Table of Contents:
1. RFA-DA-19-003 Exploiting Omics Assays to Investigate Molecular Regulation of Persistent HIV in Individuals with Substance Use Disorder (R61/R33 Clinical Trial Optional)
2. PAR-17-242/250 Extracellular Vesicles and Substance Use Disorders (R21/R01)
3. PAR-18-742 Exploring Epigenomic or Non-Coding RNA Regulation in the Development, Maintenance, or Treatment of Chronic Pain (R61/R33 Clinical Trial Optional)
4.RFA-DA-19-037 Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: CNS Data Generation (UM1 Clinical Trial Not Allowed)
5. RFA-DA-19-038 Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Coordination, Analysis, and Scientific Outreach (UM1 Clinical Trial Not Allowed)
1. RFA-DA-19-003 Exploiting Omics Assays to Investigate Molecular Regulation of Persistent HIV in Individuals with Substance Use Disorder (R61/R33 Clinical Trial Optional)
Purpose: This initiative will support projects that exploit Omics assays to address outstanding questions regarding molecular regulation of persistent HIV (e.g. latency or reservoirs) in the context of chronic substance use or substance use disorder (SUD).
AIDS Application Due Date(s): July 17, 2019 and July 17, 2020 by 5:00 PM local time of applicant organization.
NIDA intends to commit $2M to fund 2-3 awards in FY2019, FY2020, and FY2021.
https://grants.nih.gov/grants/guide/rfa-files/rfa-da-19-003.html
2. PAR-17-242/250 Extracellular Vesicles and Substance Use Disorders (R21/R01)
Purpose: To encourage research projects that investigate the interplay between extracellular vesicles (EVs) and substance use disorders (SUDs). In particular, NIDA is interested in the potential utility of EVs with respect to understanding neuroplastic mechanisms relevant to SUDs or as biomarkers or therapeutics.
Application Due Date(s): November 3, 2019, March 3, 2020
https://grants.nih.gov/grants/guide/pa-files/par-17-250.html
3. PAR-18-742 Exploring Epigenomic or Non-Coding RNA Regulation in the Development, Maintenance, or Treatment of Chronic Pain (R61/R33 Clinical Trial Optional)
Purpose: To encourage research that investigates the role of epigenetic or non-coding RNA regulatory pathways in the development, maintenance, or treatment of chronic pain. Ultimately research in the area will provide foundational knowledge that can be exploited to develop novel and non-addictive pain medications or to develop biomarkers that predict chronic pain progression or treatment response.
Application Due Date(s): July 17, 2019, November 13, 2019, February 11, 2020, July 17, 2020, November 13, 2020, February 11, 2021
https://grants.nih.gov/grants/guide/pa-files/par-18-742.html
(RFA-DA-19-037)
National Institute on Drug Abuse
Application Receipt Date(s): May 8, 2019 and October 8, 2019), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
RFA-DA-19-037 Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: CNS Data Generation (UM1) will support projects proposing to generate single cell or single nucleus RNA-sequencing data sets for at least one brain region relevant to persistent HIV infection and opioid use disorder. If fully successful, this project will generate 1. a cellular “parts list” for at least one NIDA-relevant brain region, 2. reveal how cell types within this brain region differ from one another with respect to gene expression, potentially enabling cell type-specific genetic or pharmacological manipulation, 3. reveal how HIV infection in the CNS influences single cells and the genes expressed within them, providing potential targets for manipulation of HIV persistence and/or HIV neurobiological sequelae, 4. reveal how cell types within this brain region are altered by chronic opioid exposure providing potential novel therapeutic targets for opioid addiction, and 5. uncover potential synergistic effects of chronic opioid exposure and HIV infection in the CNS.
NIDA intends to commit $4M in FY19 and $4M in FY20 to fund 1-2 applications for each receipt date.
Application budgets are not limited but need to reflect the actual needs of the proposed project.
The maximum project period is 5 years.
The purpose of this FOA is to support generation of single cell RNA-sequencing datasets for at least one brain region relevant to persistent HIV infection and opioid use disorder. Applications that are not responsive to this FOA will be returned without review. To be responsive to this FOA, proposed projects should be framed to answer one or more vexing questions about persistent HIV infection in the CNS. The major thrust of the proposed project also MUST:
o exploit single nucleus or single cell transcriptomic assays with the goal of identifying the types of cells within at least one NIDA-relevant brain region (e.g. PFC, NAc, VTA, striatum, insula, or other appropriately justified region) and how the cell types and individual cells within that region differ from one another in terms of gene expression.
o focus on human post-mortem brain tissue from controls, individuals with chronic opioid exposure, HIV-infected individuals, and HIV-infected individuals with chronic opioid exposure.
o propose to detect HIV proteins or RNA or DNA within the single cells or nuclei to be assayed.
(RFA-DA-19-038)
National Institute on Drug Abuse
Application Receipt Date(s): May 8, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Through RFA-DA-19-038, a SCORCH data coordination, analysis, and scientific outreach center will be established to standardize and share single cell molecular HIV/SUD data generated by this program by ensuring that the data is FAIR (Findable, Accessible, Interoperable, and Reusable). The SCORCH Data Center will also integrate other molecular HIV/SUD data sets generated by NIDA-funded investigators to maximize their value to the scientific community. This data center is expected to leverage knowledge and resources generated by BICCN, HuBMAP, and other single cell initiatives to maximize scientific understanding. Harmonized molecular and single cell HIV/SUD data sets will enable near term data mining by the scientific community to identify HIV and/or SUD biomarkers and identify candidate pathways for therapeutic intervention. The SCORCH Data Center will also enable future mining of these data sets as new and improved data science and information technology approaches are developed, maximizing NIDA’s original investment in the data generating activities.
NIDA intends to commit $1M in FY19 to fund one application.
Application budgets are not limited but need to reflect the actual needs of the proposed project.
The maximum project period is 5 years.
The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L in the message body of the email - You will receive a confirmation email if successful. If you have problems contact jpollock@mail.nih.gov 301-435-1309
No comments:
Post a Comment